Drug Trial Radar · NCT02138916
Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History
Last checked: Nov 20, 2026Latest source record: Jun 13, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,656
Actual
Start
Jun 13, 2014
Primary completion
Apr 10, 2018
Study completion Apr 10, 2018
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- MedImmune LLC
- First posted
- May 15, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 40 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to determine if benralizumab reduces COPD exacerbation rate in symptomatic patients with moderate to very severe COPD who are receiving standard of care therapies
Conditions
- Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Interventions
Benralizumab Arm ADrug
Benralizumab subcutaneously on study week 0 until study week 48 inclusive
Benralizumab Arm BDrug
Benralizumab subcutaneously on study week 0 until study week 48 inclusive
PlaceboDrug
Placebo subcutaneously on study week 0 until study week 48 inclusive
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annual COPD Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS>=220/uLTime frame: From first IP to week 56
Locations
407 sites in 17 countries. Site status is shown where the registry gives one.
Research Site
Andalusia, Alabama
Research Site
Birmingham, Alabama
Research Site
Birmingham, Alabama
Research Site
Dothan, Alabama
Research Site
Jasper, Alabama
Research Site
Little Rock, Arkansas
Research Site
Beverly Hills, California
Research Site
Gold River, California
Research Site
Huntington Beach, California
Research Site
Huntington Park, California
Research Site
Lakewood, California
Research Site
Lomita, California
Research Site
Newport Beach, California
Research Site
Palm Desert, California
Research Site
Palo Alto, California
Research Site
Riverside, California
Research Site
Sacramento, California
Research Site
San Diego, California
Research Site
Santa Ana, California
Research Site
Thousand Oaks, California
Research Site
Torrance, California
Research Site
New Haven, Connecticut
Research Site
Waterbury, Connecticut
Research Site
Boynton Beach, Florida
Research Site
Brandon, Florida
Research Site
Clearwater, Florida
Research Site
Clearwater, Florida
Research Site
Fort Lauderdale, Florida
Research Site
Gainesville, Florida
Research Site
Hialeah, Florida
Research Site
Kissimmee, Florida
Research Site
Loxahatchee Groves, Florida
Research Site
Miami, Florida
Research Site
Miami, Florida
Research Site
Miami, Florida
Research Site
Miami, Florida
Research Site
Miami Springs, Florida
Research Site
Orlando, Florida
Research Site
Orlando, Florida
Research Site
Orlando, Florida
Showing 40 of 407 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.